|Bid||484.94 x 800|
|Ask||485.91 x 1100|
|Day's Range||479.36 - 487.77|
|52 Week Range||228.67 - 488.23|
|Beta (5Y Monthly)||1.12|
|PE Ratio (TTM)||105.98|
|Earnings Date||Aug 05, 2021|
|Forward Dividend & Yield||1.28 (0.27%)|
|Ex-Dividend Date||May 14, 2021|
|1y Target Est||457.22|
Bio-Techne Corporation (NASDAQ: TECH) today announced that scientists at the U.S. Centers for Disease Control and Prevention (CDC) recently highlighted the importance of fixed tissue analysis for retrospective diagnosis of SARS-CoV-2 infection and characterization of viral strains, particularly for fatal cases in which no previous testing for SARS-CoV-2 was performed.
Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host its 2021 Investor Day on Friday, September 10, 2021, starting at 9:00 a.m. EDT. The meeting will take place at the Lotte New York Palace Hotel, 455 Madison Avenue, New York City.
Bio-Techne Corporation (NASDAQ: TECH) and PROGEN today announced the launch of the Simple Plex™ Adeno-Associated Virus (AAV2) viral titer assay for AAV2 total capsid quantification. Bio-Techne, owner of the leading ProteinSimple branded protein analysis portfolio of products, and PROGEN will offer the Simple Plex AAV2 viral titer assay on Ella™ instruments, its multiplexing immunoassay system. Combining the efficiency and reproducibility of the established AAV2 ELISAs from PROGEN with the conven